Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.57 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27541379 | 0.81 | DBH (0.51) | LMNAHTTALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL27413199 | 0.78 | TAAR1 (0.38) | LMNAMAP3K14PTGER3ALDH1A1 | |
| SCHEMBL3195921 | 0.76 | ALDH1A1 (0.52) | LMNAHTTALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL27595895 | 0.75 | ALDH1A1 (0.63) | LMNAHTTALDH1A1MEN1KMT2A | |
| SCHEMBL28299874 | 0.75 | PTGER3 (0.50) | LMNAMAP3K14PTGER3HTTSMN1; SMN2 | |
| SCHEMBL28003319 | 0.74 | POLB (0.69) | LMNAMAP3K14PTGER3ALDH1A1SMN1; SMN2 | |
| SCHEMBL28477446 | 0.74 | ALDH1A1 (0.61) | LMNAMAP3K14PTGER3HTTALDH1A1 | |
| SCHEMBL31590921 | 0.73 | VEGFA (0.54) | HTTATMSMN1; SMN2KMT2AMAPT | |
| SCHEMBL31466359 | 0.73 | LMNA (0.77) | LMNAMAP3K14PTGER3ALDH1A1SMN1; SMN2 | |
| SCHEMBL1770083 | 0.73 | EGLN1 (0.62) | LMNAMAP3K14PTGER3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193041-A1 | NOVEL COMPOUND AND METHOD FOR PREVENTING OR TREATING OF RESPIRATORY DISEASES COMPRISING THE SAME AS AN ACTIVE INGREDIENT | Yonsei University, University - Industry Foundation (UIF) (KR) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193041-A1 | NOVEL COMPOUND AND METHOD FOR PREVENTING OR TREATING OF RESPIRATORY DISEASES COMPRISING THE SAME AS AN ACTIVE INGREDIENT | EPX, CFTR, MPO | LMNA 393/4885MAP3K14 3845/4885PTGER3 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.